Eli Lilly And Company

This study tests a new weekly injection called eloralintide to help adults with obesity or overweight lose weight. About 1,980 participants will receive either the drug or a placebo for up to 75 weeks, with an extension for those with prediabetes. The main goal is to see how much…

This early-phase study tests a new medicine called LY3938577 in healthy volunteers and people with type 1 diabetes. The main goals are to check how the drug moves through the body, its safety, and any side effects. Later parts of the study will compare its blood sugar-lowering ef…

This study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab therapy helps adults with moderate-to-severe plaque psoriasis who are also overweight or obese. About 200 participants will receive both treatments for up to 12 months. The main goals are t…

This study is for cancer patients who took part in an earlier Eli Lilly study and were still benefiting from the treatment when that study ended. It allows them to keep receiving the study drug so their disease can continue to be managed. The main goal is to monitor long-term saf…

This early-phase study tests a new drug, LY4337713, that delivers radiation directly to cancer cells with a specific protein called FAP. It is for adults with advanced or spread cancers like pancreatic, breast, ovarian, or colorectal cancer that have not responded to other treatm…

This study tests a new once-weekly medicine called eloralintide for adults who are still obese or overweight despite taking another weight-loss drug. About 900 participants will receive either eloralintide or a placebo for around 80 weeks. The goal is to see if the new drug helps…

This study tests whether baricitinib, a daily pill, can safely regrow hair in children aged 6 to 17 with severe alopecia areata (a condition causing patchy or total hair loss). About 595 kids will receive either the drug or a placebo for 36 weeks, followed by a longer extension p…

This early-stage study tests a new drug called LY4006895 in healthy volunteers and people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body processes it. About 128 participants will take either the drug or a placebo, and the study last…

This study tests a once-daily pill called orforglipron to see if it can lower blood pressure in people who have hypertension and are also overweight or have obesity. About 487 participants will receive either the study drug or a placebo. The main goal is to measure changes in blo…

This study tests a once-weekly medicine called tirzepatide in 3000 adults with obesity (but not diabetes) to see how much weight they lose and whether it prevents type 2 diabetes. Participants will be followed for about 5 years in real-world clinics. The medicine is compared to s…

This study tests a new drug, LY4052031, in people with advanced or spreading solid tumors, including bladder, breast, and lung cancers. The drug is designed to attach to a protein on cancer cells and deliver a toxic payload to kill them. The trial has two parts: first to find the…

This early-phase study tests the safety of a new injectable drug, LY3971297, in healthy volunteers and people with obesity and high blood pressure. Researchers will monitor side effects and measure how the drug moves through the body. The study involves up to 225 participants acr…

This study tests an oral medication called orforglipron, taken once daily, to see if it helps teenagers with obesity or overweight (with related health issues) lose weight. About 125 teens will receive either the drug or a placebo for roughly 18 months. The main goal is to measur…

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo through an IV. The goal is to see if the drug can regrow hair and is safe, with the stud…

This study tests whether adding an experimental drug (LY4268989) to an existing treatment (mirikizumab) works better than the existing treatment alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive either the combination or mirikizumab …

This study tests a new medicine, sofetabart mipitecan, in people with ovarian, fallopian tube, or peritoneal cancer. Part A includes those whose cancer no longer responds to platinum chemotherapy, and Part B includes those whose cancer still responds. The goal is to see if the ne…

This study tests whether certain medicines can help teenagers (ages 12 to 17) with obesity or overweight manage their weight over the long term. Participants must have tried and failed a structured diet and exercise program for at least 3 months. The trial will compare the safety…

This early-stage study tests a new medicine called LY4167586 in people with obesity or overweight who are otherwise healthy. The main goal is to check if the drug is safe and how the body processes it after a single dose. About 84 participants will receive either the drug or a pl…

This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and pancreatic cancers. The drug is designed to target and kill cancer cells that have a specific marker (folate receptor alpha). The trial has two parts: first, finding the …

This study tests whether adding a weight-loss drug (tirzepatide) to a standard Crohn's treatment (mirikizumab) helps people with both Crohn's disease and obesity or overweight. About 290 adults will receive either mirikizumab alone or mirikizumab plus tirzepatide for up to 61 wee…

This early-stage study is testing a new drug called LY4213663 in healthy volunteers and people with rheumatoid arthritis (RA). The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also study how the body processes the drug. The study la…

This study tests an oral medication called LY4268989 in about 1,400 adults with moderate to severe ulcerative colitis. The goal is to see if it can safely reduce symptoms and help the bowel heal compared to a placebo. Participants will take the pill for up to 108 weeks and be mon…

This study tests a once-daily pill called orforglipron to see if it can lower blood pressure in people who have both high blood pressure and obesity or overweight. About 487 adults will take either the study drug or a placebo. The main goal is to measure changes in blood pressure…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and a CDK4/6 inhibitor can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not yet received treatment for advanced disease will participate. The go…

This study tests whether baricitinib, a pill, can help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. About 300 children and young adults aged 1 to 36 will take either baricitinib or a placebo for 60 weeks. The goal is to see if the dr…

This study tests whether baricitinib is safe and effective for children aged 1 to 18 with systemic juvenile idiopathic arthritis (sJIA), a condition that causes joint swelling and fever. About 58 children will receive either baricitinib or an existing drug called tocilizumab. The…

This study tests whether adding a new targeted drug (vepugratinib) to two standard cancer treatments helps adults with advanced bladder cancer that has a specific FGFR3 gene change. About 450 participants will receive either the new drug or a placebo, plus the standard treatments…

This study tests a new drug, LOXO-435, in people with advanced solid tumors, especially bladder cancer, that have a change in the FGFR3 gene. The goal is to find the best dose and see if the drug is safe and can shrink tumors. About 535 adults will take part for up to 2.5 years.

This study tests a new oral drug, pirtobrutinib, for adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The trial has two parts: first, finding safe doses in about 58 participants, then comparing the drug to a…

This study tests whether adding brenipatide to standard schizophrenia medication works better than standard care alone. About 450 adults with schizophrenia will take either brenipatide or a placebo for up to 12 months. The goal is to see if it helps control symptoms and reduces t…

This study tests a new medicine called brenipatide to see if it helps people with moderate-to-severe alcohol use disorder drink less and reduce cravings. About 1,100 adults who want to cut down or stop drinking will receive either the drug or a placebo for 56 weeks. The main goal…

This study tests whether adding a new targeted drug (LY3537982) to standard treatments can better control advanced non-small cell lung cancer with a specific KRAS G12C gene change. About 1,264 people with untreated, advanced disease will receive either the new drug combo or stand…

This study tests a new drug, LY3537982, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile du…

This early-stage study tests a new medicine called LY4006896 in healthy people and those with Parkinson's disease. The main goal is to check if the drug is safe and how the body processes it. About 127 participants will receive either the drug or a placebo by IV. This is a first …

This study tests whether adding the experimental drug olomorasib to standard immunotherapy can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C mutation). The trial has two parts: one for patients whose cancer was removed by surgery but had res…

This study tests a new drug, STX-478, in people with advanced solid tumors (like breast cancer) that have a specific genetic change called PI3Kα mutation. The drug is given alone or with other cancer treatments. The goal is to see if it is safe and helps shrink tumors. About 880 …

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were in a previous trial. Participants will either keep taking the drug or continue follow-up visits. The goal is to monitor side…

This study tests whether the drug orforglipron can reduce major heart problems like heart attacks, strokes, and heart failure in people with heart or kidney disease. About 7,140 participants will receive either the drug or a placebo for up to 5 years. The goal is to see if orforg…

This study tests whether a new drug called brenipatide can help adults whose moderate-to-severe asthma is not well controlled by current treatments. About 531 participants will receive either brenipatide or a placebo for 52 weeks. The goal is to see if brenipatide reduces asthma …

This early-stage study tests whether retatrutide can improve how the body uses insulin and controls blood sugar in adults with type 2 diabetes. About 95 participants who already take metformin will receive retatrutide, a similar drug called semaglutide, or a placebo for 28 weeks.…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced breast, colorectal, prostate, or endometrial cancer that has spread. The goal is to see if the drug is safe and shrinks tumors. …

This study tests a medicine called brenipatide to see if it helps adults with alcohol use disorder drink less and reduce cravings. About 1,100 people will take either the drug or a placebo for 56 weeks. The goal is to find a safe, effective treatment to help people cut down or st…

This study tests whether adding an experimental drug called brenipatide to standard treatment (buprenorphine) helps people with opioid use disorder stay off opioids longer. About 465 participants will receive either brenipatide or a placebo injection over many weeks. The goal is …

This early-stage study tests a new drug called brenipatide in healthy adults who are overweight or have obesity. The goal is to see how well different doses help with weight loss and whether they are safe. Participants will receive injections under the skin and be followed for ab…

This study tests a new medicine called LY3938577 against a standard insulin (degludec) in 100 adults with type 2 diabetes who already use basal insulin. The goal is to see if the new drug helps keep blood sugar in a healthy range more safely and effectively over about 26 weeks. P…

This study tests a new once-weekly injection called eloralintide to help people with obesity or overweight and type 2 diabetes lose weight. About 1035 adults will receive either the drug or a placebo for 75 weeks. The main goal is to see how much weight they lose and whether it a…

This study tests a new weekly injection, LY3457263, in adults with type 2 diabetes whose blood sugar is still too high despite taking stable doses of semaglutide or tirzepatide. About 240 participants will receive either the new drug or a placebo for roughly 9 months. The main go…

This early-stage study tests a new drug called LY4256984 in 32 people with sporadic ALS. The drug is given as an injection into the spine to see if it is safe and what side effects it may cause. Researchers will also measure how much drug gets into the blood and how the body proc…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard treatments. The drug is designed to seek out and attack cancer cells carrying a specific marker (PTK7). The main goals are…

This early-stage study tests a new medicine called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it. About 63 participants will receive either the drug or a placebo, and the …

This study tests two higher doses of the diabetes drug dulaglutide in 55 teenagers aged 10 to 17 who have type 2 diabetes. Participants must already be on metformin or basal insulin. The goal is to see if the higher doses are safe and help control blood sugar and weight over abou…

This study tests a drug called mirikizumab in children aged 2 to 17 with moderate-to-severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can help control the disease and improve symptoms. About 60 children will take part, and they will receive the d…

This study looks at whether adding tirzepatide (a drug used for diabetes and weight loss) to the standard psoriatic arthritis treatment ixekizumab helps people with active psoriatic arthritis who are also overweight or obese. About 200 adults will take both drugs for up to 12 mon…

This study tests whether an experimental drug called LY4065967 can safely reduce nerve pain in people with diabetes. About 150 adults with diabetic nerve pain in their legs for at least 6 months will receive either the drug or a placebo. The main goal is to see if the drug lowers…

This study tests a drug called lebrikizumab in 200 adults and teenagers who have moderate eczema but suffer from severe itching. The goal is to see if the drug can significantly reduce itch and clear skin patches over 6 months of treatment. Participants will receive the drug alon…

This study tests whether a once-daily tablet called orforglipron can reduce episodes of stress urinary incontinence (leaking urine during activity) in women who have obesity or overweight. About 1000 adult women will receive either the drug or a placebo for up to 58 weeks. The ma…

This early-stage study tests a new drug called LY4064912 in healthy volunteers and people with overweight or obesity. The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug and its effect on bo…

This phase 3 study tests a once-weekly medicine called eloralintide in 900 adults who have osteoarthritis of the knee and are overweight or have obesity. The goal is to see if the drug reduces knee pain and body weight better than a placebo. Participants will be in the study for …

This study tests a once-daily medication called orforglipron in people with peripheral artery disease (PAD), a condition that causes leg pain while walking due to narrowed arteries. The goal is to see if the drug can increase how far participants can walk without pain and improve…

This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver issues compared to those with healthy livers. About 33 adults will receive a single injection under the skin and be monitored for up to 9 weeks. The goal is to …

This study looks at how a single shot of eloralintide affects people with mild, moderate, or severe liver damage compared to those with healthy livers. Researchers want to see how the drug moves through the body and if it causes side effects. The study involves 36 adults and last…

This early-stage study tests an experimental drug called LY4088044 in healthy people to see if it is safe and how the body processes it. About 104 participants will receive the drug or a placebo, either as a shot under the skin or into a vein. The study lasts up to 92 weeks and i…

This study looks at how fluconazole, a common antifungal, changes the way the body handles olomorasib, an experimental drug. Fifteen healthy adults will take both drugs and have their blood levels measured. The study lasts about 7 weeks and includes 12 overnight stays at the rese…

This study measures how much of the drug olomorasib gets into the blood and how fast the body clears it. About 120 healthy adults will take the drug by mouth in three different sequences. The study lasts about 7 weeks and includes 10 overnight stays at a research center.

This study follows 3,400 adults who report no memory problems for about 7 years. Researchers will regularly test their thinking skills and measure a blood protein (P-tau217) linked to Alzheimer's. The goal is to see how quickly cognitive decline happens in people with high versus…

This early-stage study tests whether the experimental drug LY4515100 is safe and tolerable in 40 healthy adults. Participants take the drug or a placebo and undergo blood tests and overnight stays over 30 days. The goal is to learn how the body processes the drug, not to treat an…

This early-stage study tests the safety of a new drug called LY4066708 in 104 healthy adults. Researchers will measure how much drug enters the blood and brain, and how fast the body clears it. The study lasts up to 24 weeks and does not aim to treat any disease, but will help gu…

This study looks at how long you fast and whether you temporarily stop taking tirzepatide affects how much food and drink stays in your stomach after a meal. Researchers will use ultrasound to check stomach contents in 40 adults with type 2 diabetes, obesity, or overweight. The g…

This early-stage study tests an experimental drug called LY3867070 in healthy people to see if it is safe and how the body handles it. About 196 healthy adults will take the drug by mouth and have blood tests. The goal is to find side effects and measure drug levels, not to treat…

This study looks at how the body processes a new drug called eloralintide in people with severe kidney disease or kidney failure compared to healthy people. About 28 adults will receive a single injection under the skin. The goal is to measure drug levels in the blood and how lon…